Aims and scope

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

  • Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.
  • Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.
  • Current Opinion articles that place interesting areas in perspective.
  • Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.
  • Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.
  • Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Targeted Oncology may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.